COVID-19
Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-235, a coronavirus 3CL protease inhibitor (also known as the main coronavirus…
Read More
— Data Supports the Continued Use of Veklury for Treatment of COVID-19 for Current SARS-CoV-2 Variants – Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today released data demonstrating the in vitro activity of Veklury® (remdesivir) against ten SARS-CoV-2 variants, including Omicron. Results of Gilead studies are consistent with other in vitro studies independently conducted…
Read More
Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaper BriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines, according to IIBR findings Excerpt from the Press Release: RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel…
Read More
– Pseudovirus results being shared with government and regulatory authorities;publication in bioRxiv anticipated in the coming week; additional live virus testing underway – Excerpt from the Press Release: SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that preclinical data suggest that sotrovimab, an investigational monoclonal antibody authorized for emergency…
Read More
– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested – – IGM-6268 Phase 1 clinical trials advancing in U.S. and South Africa – Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq:…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. According to the Centers for Disease Control and Prevention, the Omicron variant of the SARS-CoV-2 virus…
Read More CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that its Investigational New Drug (IND) application for PBI-0451 has been cleared…
Read More
Excerpt from the Press Release: PHILADELPHIA — (Feb. 1, 2022) — The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants. Now scientists at The Wistar Institute have developed a more targeted vaccine that, in animal studies, shows stronger,…
Read More
Data show bemnifosbuvir’s unique mechanism of action increases barrier for emergence of resistance, making it an ideal candidate for treatment of COVID-19 and for combination therapy Excerpt from the Press Release: BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir…
Read More Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including participants who received the two-dose primary series and a 50 µg booster dose of mRNA-1273 Omicron neutralization six months after the third 50 µg dose of mRNA-1273 declined, but remained…
Read More